## UNITED STATES SECURITIES AND EXCHANGE COMMISSION May 4, 2017

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933 AND THE SECURITIES EXCHANGE ACT OF 1934

Tokai Pharmaceuticals, Inc. File Nos. 333-198052 and 1-36620

## CF#35000

-----

Tokai Pharmaceuticals, Inc. submitted an application under Rules 406 and 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the Exhibits to Form S-1 filed on August 11, 2014 and Form 10-Q filed on May 10, 2016.

Based on representations by Tokai Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

			Confidential Treatment
<b>Exhibit</b>	to Form	Filed on	Granted
10.14	S-1	August 11, 2014	through May 2, 2020
10.1	10-Q	May 10, 2016	through May 2, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary